Insulin resistance but not visceral adipose tissue is associated with plasminogen activator inhibitor type 1 levels in overweight and obese premenopausal African-American women

International Journal of Obesity

Volumn 27, Issue 1, 2003, Pages 82-87

  Solano, M P ^a,b   Perry, A C ^b   Wang, X ^b   Ross, R ^c   Goldberg, R B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

Fibrinolysis; Insulin resistance PAI 1; Metabolic syndrome; Premenopausal women; Visceral adipose tissue

Indexed keywords

GLUCOSE; INSULIN; LEPTIN; LIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY FAT; BODY MASS; BODY WEIGHT; CAUCASIAN; CONTROLLED STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; MULTIPLE REGRESSION; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN DETERMINATION; RACE; RACE DIFFERENCE; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOSE TISSUE; ADULT; AFRICAN AMERICANS; BODY WEIGHT; DIET; EXERCISE; FEMALE; HUMANS; INFANT, NEWBORN; INSULIN RESISTANCE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREMENOPAUSE; VISCERA;

EID: 0037261178     PISSN: 03070565     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.ijo.0802192     Document Type: Article

References (46)

1. Larsson B. Obesity, fat distribution and cardiovascular disease. Int J Obes 1991; 15: 53-57.
2. Bjorntorp P. Abdominal fat distribution and disease: an overview of epidemiological data. Ann Med 1992; 24: 15-18.
3. Reaven GM. Pathogenesis of insulin resistance in human and disease. Physiol Rev 1995; 75: 473-486.
4. Juhan-Vague I, Alessi MC. PAI-1, obesity, insulin resistance and risk of cardiovascular events. Thromb Haemost 1997; 78: 656-660.
5. Juhan-Vague I, Alessi MC, Vague P. Increased plasma plaminogen activator inhibitor-1 levels: a possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457-462.
6. Lindahl B, Asplund K, Eliasson M, Evrin PE. Insulin resistance syndrome and fibrinolytic activity: the northern Sweden MONICA study. Int J Epidemiol 1996; 25: 291-299.
7. Festa A, D'Agostino R Jr, Mykkanen L, Tracy RP, Zaccaro DJ, Hales CN, Haffner SM. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 1999; 19: 562-568.
8. Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinska I, D'Agostino RB, Wilson PW. Hyperinsulinemia, hyperglycemia and impaired hemostasis: the Framingham Offspring Study. JAMA 2000; 283: 221-228.
9. Vague P, Juhan-Vague I, Aillaud MF, Badier C, Viard R, Alessi MC, Collen D. Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 1986; 35: 250-253.
10. Vague P, Juhan-Vague I, Chabert V, Allesi MC, Atlan C. Fat distribution and plasminogen activator inhibitor activity in non-diabetic obese women. Metabolism 1989; 38: 913-915.
11. Janand-Delenne B, Chagnaud C, Raccah D, Alessi MC, Juhan-Vague I, Vague P. Visceral fat as a main determinant of plasminogen activator inhibitor 1 level in women. Int J Obes Relat Metab Disord 1998; 22: 312-317.
12. Giltay EJ, Elbers JMH, Gooren LJG, Emeis JJ, Kooistra T, Asscheman H, Stehouwer CD. Visceral fat accumulation is an important determinant of PAI-1 levels in young, non obese men and women. Modulation by cross-sex hormone administration. Arterioscler Thromb Vasc Biol 1998; 18: 1716-1722.
13. Mussoni L, Mannuci L, Sirtori M, Camera M, Maderna P, Sironi L, Tremoli E. Hypertriglyceridemia and regulation of fibrinolytic activity. Arterioscler Thromb 1992; 12: 19-27.
14. Asplund-Carlson A, Hamsten A, Wiman B, Carlson LA. Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia 1993; 36: 817-825.
15. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996; 2: 800-803.
16. Crandall DL, Quinet EM, Morgan GA, Busler DE, McHendry-Rinde B, Kral JG. Synthesis and secretion of plasminogen activator inhibitor-1 by human preadipocytes. J Clin Endorinol Metab 1999; 84: 3222-3227.
17. Erkisson P, Reynisdottir S, Lonnqvist F, Stemme V, Hamsten A, Arner P. Adipose tissue secretion of plasminogen activator inhibitor-1 in non-obese and obese individuals. Diabetologia 1998; 41: 65-71.
18. Alessi MC, Peiretti F, Morangue P, Henry M, Nalbone G, JuhanVague I. Production of plasminogen activator inhibitor 1 by human adipose tissue. Possible link between visceral fat accumulation and vascular disease. Diabetes 1997; 46: 860-867.
19. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults: the National Health and Nutritional Examination Surverys, 1960-1991. JAMA 1994; 272: 205-211.
20. Kumanyika SK. Obesity in black women. Epidemiol Rev 1987; 9: 31-50.
21. Adams-Campbell LL, Nwankwo M, Omene J, Haile GT, Kuller LH. Body fat distribution patterns and blood pressure in black and white women. J Natl Med Assoc 1990; 82: 573-576.
22. Wing RR, Kuller LH, Bunker C, Matthews K, Caggiula A, Meihlan E, Kelsey S. Obesity, obesity-related behaviors, and coronary heart disease risk factors in black and white premenopausal women. Int J Obes 1989; 13: 511-519.
23. Zillikens MC, Conway JM. Anthropometry in blacks: applicability of generalized skinfold equations and differences in fat patterning between black and whites. Am J Clin Nutr 1990; 52: 45-51.
24. Perry AC, Applegate EB, Jackson ML, Deprima S, Goldberg RB, Ross R, Kempner L, Feldman BB. Racial differences in visceral adipose tissue but not anthropometric markers of health-related variables. J Appl Physiol 2000; 89: 636-643.
25. Conway JM, Yanovski SZ, Avila NA, Hubbard VS. Visceral adipose tissue differences in black and white women. Am J Clin Nutr 1995; 61: 765-771.
26. Lovejoy JC, de la Bretonee JA, Klemperer M, Tulley R. Abdominal fat distribution and metabolic risk factors: effects of race. Metabolism 1996; 45: 1119-1124.
27. Karter AJ, Mayer-Davis EJ, Selby JV, D'Agostino RB Jr, Haffner SM, Sholinsky P, Bergman R, Saad MF, Hamman RF. Insulin sensitivity and abdominal obesity in African-American, Hispanic, and non-Hispanic white men and women. The Insulin Resistance and Atherosclerosis Study. Diabetes 1996; 45: 1547-1555.
28. Dowling HJ, Pi-Sunyer X. Race-dependent health risks of upper body obesity. Diabetes 1993; 42: 537-543.
29. Albu JB, Murphy L, Frager DH, Johnson JA, Pi-Sunyer FX. Visceral fat and race-dependent health risks in obese nondiabetic premenopausal women. Diabetes 1997; 46: 456-462.
30. Segal KR, Van Loan M, Fitzgerald PI, Hodgdon JA, Van Itallie TB. Lean body mass estimation by bioelectrical impedance analysis: a four-site cross-validation study. Am J Clin Nutr 1988; 47: 7-14.
31. Goran MI, Khaled, MA. Cross-validation of fat-free mass estimated from body density against bioelectrical resistance: effects of obesity and gender. Obes Res 1995; 3: 531-539.
32. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RL. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
33. Friedewald WT, Levy RS, Fredrickson DS. estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
34. Ross R, Leger L, Morris D, de Guise J, Guardo R. Quantification of adipose tissue by MRI: relationship to antthropometric variables. J Appl Physiol 1992; 72: 787-795.
35. Kooistra T, Bosma PJ, Tons HAM, van den Berg AP, Meyer P, Princen HMG. Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased by insulin in cultured human hepatocytes. Thromb Haemost 1989; 62: 723-728.
36. Schneider DJ, Absher PM, Ricci MA. Dependance of augmentation of arterial endothelial cell expression of plasminogen activator inhibitor type 1 by insulin on soluble factors released from vascular smooth muscle cells. Circulation 1997; 96: 2868-2876.
37. Potter Van Loon BJ, de Bart ACW, Radder JK, Frouch M, Kluft C, Menders AE. Acute exogenous hyperinsulinemia does not result in elevation of plasma plasminogen activator inhibitor 1 (PAI-1) in human. Fibrinolysis 1990; 4: 93-94.
38. Vuorinen-Markkola H, Puhakainen I, Yki-Jarvinen H. No evidence for short-term regulation of plasminogen activator inhibitor in man. Thromb Haemost 1992; 67: 117-120.
39. Landin K, Tengborn L, Chmielewska J, von Schenk H, Smith U. The acute effect of insulin on tissue plasminogen activator inhibitor in man. Thromb Haemost 1991; 65: 130-133.
40. Eriksson P, Van Harmelen V, Hoffsteadt J, Lundquist P, Vidal H, Stemme V, Hamsten A, Arner P, Reynisdottir S. Regional Variation in plasminogen activator inhibitor-1 expression in adipose tissue from obese individuals. Thromb Haemost 2000; 83: 545-548.
41. Hill JO, Sidney S, Lewis CE, Tolan K, Scherzinger AL, Stamm ER. Racial differences in amounts of visceral adipose tissue in young adults: the CARDIA (Coronary Artery Risk Development in Young Adults) study. Am J Clin Nutr 1999; 69: 381-387.
42. Blair D, Habicht J-P, Sims EAH, Sylwester D, Abraham S. Evidence for an increased risk of hypertension with centrally located body fat and the effect of sex and race on this risk. Am J Epidemiol 1984; 119: 526-540.
43. Stevens J, Keil JE, Rust PF, Tyroler HA, Davis CE, Gazes PC. Body mass index and body girths as predictors of mortality in black and white women. Arch Intern Med 1992; 152: 1257-1262.
44. Juhan-Vague I, Pyke SDM, Alessi MC, Jespersen J, Haverkate F, Thompson SG, on behalf of the ECAT Study Group. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94: 2057-2063.
45. Cigolini M, Targher G, Seidell JC, Tonoli M, Schiavon R, Agostino G, De Sandre G. Relationships of blood pressure to fibrinolysis: influence of anthropometry, metabolic profile and behavioral variables. J Hypertens 1995; 3: 659-666.
46. Jeng JW, Sheu HH, Jeng C, Huang S, Shieh S. Impaired fibrinolysis and insulin resistance in hypertension. Am J Hypertens 1996; 26: 484-490.